Intervet Receives USDA Approval for Innovax™-SB-ND

26 February 2007
Millsboro, Delaware

The first worldwide recombinant vvMD- ND Vaccine 

Intervet Inc. announces it has received approval by the United States Department of Agriculture (USDA) for Innovax™-SB-ND, the first recombinant vaccine for protection against very virulent Marek’s Disease and Newcastle Disease viruses for the vaccination of 18-day-old chick embryos.
 
 “As both the global and U.S. leader in poultry vaccines, Intervet always seeks innovative products and solutions,” says Gary Tiller, Director of the Intervet Integrated Production Industry Business Team.  “Innovax is the first HVT vectored Newcastle Disease recombinant vaccine to reach the market.  It demonstrates Intervet’s commitment to the poultry industry and to providing safe and efficacious vaccines for poultry producers” adds Tiller.

For more information about Innovax-SB-ND, and the full line of Intervet poultry products and services, contact Intervet Customer Service at 1-800-441-8272.